Denali Therapeutics Inc. DNLI Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$128.45M+3.4% | -$128.55M-12.0% | -$126.9M-18.4% | -$124.12M-25.3% | -$132.97M-30.6% | ||
| $2.85M+22.4% | $2.87M+54.7% | $2.95M+60.3% | $3.05M+56.8% | $2.33M+7.5% | ||
| $23.09M-8.2% | $23.95M-4.5% | $25.14M+1.1% | $25.39M+1.1% | $25.16M-9.6% | ||
| -$131.2M+0.2% | -$98.54M-17.7% | -$107.3M-81.4% | -$75.3M+17.5% | -$131.47M-15.7% | ||
| $2.47M-51.4% | $1.52M-70.1% | —— | $4.28M-10.6% | $5.08M+136% | ||
| $94.46M+404% | $20.77M— | $57.83M— | $157.94M— | $18.75M+104% | ||
| $219.04M+5,923% | $192.13M— | -$778K— | $1.62M-76.0% | -$3.76M-101% | ||
| $182.3M+257% | $114.36M+35.6% | -$50.24M— | $84.26M— | -$116.48M-75.1% | ||
| -$133.67M+2.1% | -$100.06M-12.7% | -$105.92M-68.1% | -$79.58M+17.1% | -$136.55M-17.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Denali Therapeutics Inc. generate?
- Denali Therapeutics Inc. (DNLI) generated -$412.3M in operating cash flow over the trailing twelve months.
- What is Denali Therapeutics Inc.'s free cash flow?
- After $13.3M of capital expenditures, Denali Therapeutics Inc.'s free cash flow was -$419.2M over the trailing twelve months, down 9.1% year over year.
- Where does Denali Therapeutics Inc.'s cash flow data come from?
- Every line is extracted from Denali Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.